|Bid||77.43 x 1300|
|Ask||85.98 x 900|
|Day's range||78.26 - 80.78|
|52-week range||71.59 - 94.20|
|Beta (5Y monthly)||0.49|
|PE ratio (TTM)||2,214.44|
|Earnings date||27 Apr 2022 - 02 May 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||116.39|
Novo Nordisk (NVO) reports better-than-expected results for Q1. Sales are aided by growth in Diabetes and Obesity Care on higher GLP-1 revenues.
Strong demand for sleep and respiratory care devices contributed to ResMed's (RMD) fiscal third-quarter sales performance.
Alnylam's (ALNY) earnings and sales fall shy of estimates in the first quarter of 2022. The company cuts 2022 guidance for net product revenues. Shares down.